KR20110044230A - 경피적 중재 심장 카테터 삽입을 위한 다비가트란 - Google Patents
경피적 중재 심장 카테터 삽입을 위한 다비가트란 Download PDFInfo
- Publication number
- KR20110044230A KR20110044230A KR1020117003645A KR20117003645A KR20110044230A KR 20110044230 A KR20110044230 A KR 20110044230A KR 1020117003645 A KR1020117003645 A KR 1020117003645A KR 20117003645 A KR20117003645 A KR 20117003645A KR 20110044230 A KR20110044230 A KR 20110044230A
- Authority
- KR
- South Korea
- Prior art keywords
- formula
- acid
- pharmaceutically acceptable
- acceptable salt
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000000747 cardiac effect Effects 0.000 title claims description 26
- 229960003850 dabigatran Drugs 0.000 title description 3
- YBSJFWOBGCMAKL-UHFFFAOYSA-N dabigatran Chemical compound N=1C2=CC(C(=O)N(CCC(O)=O)C=3N=CC=CC=3)=CC=C2N(C)C=1CNC1=CC=C(C(N)=N)C=C1 YBSJFWOBGCMAKL-UHFFFAOYSA-N 0.000 title description 3
- 230000001404 mediated effect Effects 0.000 title description 2
- 150000003839 salts Chemical class 0.000 claims abstract description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 16
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 22
- 150000001875 compounds Chemical class 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 16
- 239000002253 acid Substances 0.000 claims description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical class CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 8
- 238000003780 insertion Methods 0.000 claims description 8
- 230000037431 insertion Effects 0.000 claims description 8
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical class OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 5
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Chemical class OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
- 239000005711 Benzoic acid Chemical class 0.000 claims description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Chemical class OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 3
- 235000010233 benzoic acid Nutrition 0.000 claims description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical class OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 3
- 239000011976 maleic acid Chemical class 0.000 claims description 3
- 229940002612 prodrug Drugs 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- KSGXQBZTULBEEQ-UHFFFAOYSA-N dabigatran etexilate Chemical compound C1=CC(C(N)=NC(=O)OCCCCCC)=CC=C1NCC1=NC2=CC(C(=O)N(CCC(=O)OCC)C=3N=CC=CC=3)=CC=C2N1C KSGXQBZTULBEEQ-UHFFFAOYSA-N 0.000 abstract description 21
- 229960000288 dabigatran etexilate Drugs 0.000 abstract description 20
- 239000008188 pellet Substances 0.000 description 22
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 17
- 235000002906 tartaric acid Nutrition 0.000 description 17
- 239000011975 tartaric acid Substances 0.000 description 17
- 239000000725 suspension Substances 0.000 description 14
- 239000002245 particle Substances 0.000 description 10
- 238000003756 stirring Methods 0.000 description 9
- 239000000203 mixture Substances 0.000 description 8
- 239000007921 spray Substances 0.000 description 8
- 239000011162 core material Substances 0.000 description 7
- 239000011149 active material Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000005507 spraying Methods 0.000 description 5
- 239000002775 capsule Substances 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 239000004205 dimethyl polysiloxane Substances 0.000 description 4
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 4
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 238000009472 formulation Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 238000013146 percutaneous coronary intervention Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 206010051055 Deep vein thrombosis Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 description 1
- 229940122388 Thrombin inhibitor Drugs 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000008807 pathological lesion Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000012106 screening analysis Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000003868 thrombin inhibitor Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
- C07D235/32—Benzimidazole-2-carbamic acids, unsubstituted or substituted; Esters thereof; Thio-analogues thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9001808P | 2008-08-19 | 2008-08-19 | |
| US61/090,018 | 2008-08-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20110044230A true KR20110044230A (ko) | 2011-04-28 |
Family
ID=41258283
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020117003645A Withdrawn KR20110044230A (ko) | 2008-08-19 | 2009-08-17 | 경피적 중재 심장 카테터 삽입을 위한 다비가트란 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20110301201A1 (enExample) |
| EP (1) | EP2328580A1 (enExample) |
| JP (1) | JP2012500245A (enExample) |
| KR (1) | KR20110044230A (enExample) |
| CN (1) | CN102123707A (enExample) |
| AR (1) | AR073077A1 (enExample) |
| AU (1) | AU2009284217A1 (enExample) |
| BR (1) | BRPI0917507A2 (enExample) |
| CA (1) | CA2734794A1 (enExample) |
| CL (1) | CL2011000361A1 (enExample) |
| CO (1) | CO6290686A2 (enExample) |
| EA (1) | EA201100358A1 (enExample) |
| EC (1) | ECSP11010825A (enExample) |
| IL (1) | IL210005A0 (enExample) |
| MA (1) | MA32563B1 (enExample) |
| MX (1) | MX2011001612A (enExample) |
| NZ (1) | NZ591108A (enExample) |
| TW (1) | TW201022235A (enExample) |
| WO (1) | WO2010020602A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2358368A1 (en) | 2008-11-11 | 2011-08-24 | Boehringer Ingelheim International GmbH | Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved safety profile over conventional warfarin therapy |
| CA2791561A1 (en) * | 2010-03-01 | 2011-09-09 | Ratiopharm Gmbh | Dabigatran etexilate-containing oral pharmaceutical composition |
| SG10201502484SA (en) | 2010-03-30 | 2015-05-28 | Verseon Corp | Multisubstituted aromatic compounds as inhibitors of thrombin |
| CN102391250B (zh) * | 2011-08-29 | 2013-06-19 | 石药集团欧意药业有限公司 | 一种达比加群酯化合物、制备方法及其药物组合物 |
| CN102558153A (zh) * | 2012-02-08 | 2012-07-11 | 北京阜康仁生物制药科技有限公司 | 达比加群酯的新药用盐及其制备方法 |
| CN103420984B (zh) * | 2012-05-24 | 2015-07-08 | 天津药物研究院 | 作为前药的达比加群酯衍生物及其制备方法和用途 |
| CN103420982B (zh) * | 2012-05-24 | 2015-07-08 | 天津药物研究院 | 达比加群酯衍生物及其制备方法和用途 |
| CN103420994B (zh) * | 2012-05-24 | 2016-04-06 | 天津药物研究院 | 作为前药的达比加群酯衍生物及其制备方法和用途 |
| CN103420985B (zh) * | 2012-05-24 | 2015-09-23 | 天津药物研究院 | 作为前药的达比加群酯衍生物及其制备方法和用途 |
| CN103524559B (zh) * | 2012-07-05 | 2016-09-28 | 西藏海思科药业集团股份有限公司 | 多取代4-甲氨基苯甲脒的酯衍生物及其制备方法和用途 |
| CN103539779B (zh) * | 2012-07-13 | 2016-12-21 | 四川海思科制药有限公司 | 一种达比加群酯的羟基取代苯磺酸盐及其制备方法和用途 |
| IN2015DN02601A (enExample) * | 2012-09-28 | 2015-09-18 | Ranbaxy Lab Ltd | |
| US9399616B2 (en) | 2012-10-22 | 2016-07-26 | Boehringer Ingelheim International Gmbh | Process for the manufacture of 4-aminobenzoamidine dihydrochloride |
| WO2014149139A2 (en) | 2013-03-15 | 2014-09-25 | Verseon, Inc. | Halogenopyrazoles as inhibitors of thrombin |
| DK2968297T3 (en) | 2013-03-15 | 2019-01-07 | Verseon Inc | MULTI-SUBSTITUTED AROMATIC COMPOUNDS AS SERINE PROTEASE INHIBITORS |
| JP2017528486A (ja) | 2014-09-17 | 2017-09-28 | ヴァーセオン コーポレイション | セリンプロテアーゼ阻害剤としてのピラゾリル置換ピリドン化合物 |
| ES2931460T3 (es) | 2015-02-27 | 2022-12-29 | Verseon Int Corporation | Compuestos de pirazol sustituido como inhibidores de serina proteasa |
| IL280078B2 (en) | 2018-07-13 | 2024-04-01 | Verseon Int Corporation | Thrombin inhibitors, formulations, and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1485094B2 (de) * | 2002-03-07 | 2020-03-25 | Boehringer Ingelheim International GmbH | Oral zu applizierende darreichungsform für 3- [(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino] -propionsäure-ethylester oder dessen salze |
| JP2008517974A (ja) * | 2004-10-25 | 2008-05-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗血栓薬と併用しての血栓塞栓性疾患の治療および予防のためのジピリダモールの使用 |
| CA2657270A1 (en) * | 2006-07-17 | 2008-01-24 | Boehringer Ingelheim International Gmbh | New paediatric indications for direct thrombin inhibitors |
| JP2009543842A (ja) * | 2006-07-17 | 2009-12-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 心臓血管分野における直接トロンビン阻害薬のための新規適応 |
| US20100087488A1 (en) * | 2006-10-10 | 2010-04-08 | Boehringer Ingelheim International Gmgh | Physiologically Acceptable Salts of 3-[(2--1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester |
-
2009
- 2009-08-17 JP JP2011523405A patent/JP2012500245A/ja active Pending
- 2009-08-17 AU AU2009284217A patent/AU2009284217A1/en not_active Abandoned
- 2009-08-17 US US13/058,920 patent/US20110301201A1/en not_active Abandoned
- 2009-08-17 EA EA201100358A patent/EA201100358A1/ru unknown
- 2009-08-17 NZ NZ591108A patent/NZ591108A/xx not_active IP Right Cessation
- 2009-08-17 MX MX2011001612A patent/MX2011001612A/es not_active Application Discontinuation
- 2009-08-17 CN CN2009801318235A patent/CN102123707A/zh active Pending
- 2009-08-17 KR KR1020117003645A patent/KR20110044230A/ko not_active Withdrawn
- 2009-08-17 CA CA2734794A patent/CA2734794A1/en not_active Abandoned
- 2009-08-17 BR BRPI0917507A patent/BRPI0917507A2/pt not_active IP Right Cessation
- 2009-08-17 WO PCT/EP2009/060592 patent/WO2010020602A1/en not_active Ceased
- 2009-08-17 EP EP09781886A patent/EP2328580A1/en not_active Withdrawn
- 2009-08-18 TW TW098127736A patent/TW201022235A/zh unknown
- 2009-08-18 AR ARP090103168A patent/AR073077A1/es unknown
-
2010
- 2010-12-15 IL IL210005A patent/IL210005A0/en unknown
-
2011
- 2011-02-11 EC EC2011010825A patent/ECSP11010825A/es unknown
- 2011-02-15 MA MA33616A patent/MA32563B1/fr unknown
- 2011-02-17 CO CO11018905A patent/CO6290686A2/es not_active Application Discontinuation
- 2011-02-18 CL CL2011000361A patent/CL2011000361A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2009284217A1 (en) | 2010-02-25 |
| AR073077A1 (es) | 2010-10-13 |
| JP2012500245A (ja) | 2012-01-05 |
| MA32563B1 (fr) | 2011-08-01 |
| TW201022235A (en) | 2010-06-16 |
| IL210005A0 (en) | 2011-02-28 |
| ECSP11010825A (es) | 2011-03-31 |
| WO2010020602A1 (en) | 2010-02-25 |
| CL2011000361A1 (es) | 2011-06-17 |
| EA201100358A1 (ru) | 2011-10-31 |
| MX2011001612A (es) | 2011-03-04 |
| BRPI0917507A2 (pt) | 2015-11-17 |
| EP2328580A1 (en) | 2011-06-08 |
| NZ591108A (en) | 2012-11-30 |
| CA2734794A1 (en) | 2010-02-25 |
| CN102123707A (zh) | 2011-07-13 |
| US20110301201A1 (en) | 2011-12-08 |
| CO6290686A2 (es) | 2011-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20110301201A1 (en) | Dabigatran for percutaneous interventional cardiac catheterisation | |
| CN100528157C (zh) | 3-[(2-{[4-(己氧羰基氨基-亚氨基-甲基)-苯基氨基]-甲基}-1-甲基-1h-苯并咪唑-5-羰基)-吡啶-2-基-氨基]-丙酸乙酯及其盐的口服施用的投药剂型 | |
| US9925174B2 (en) | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonyl-amino-imino-methyl)-phenylamino]-methyl}-1-methyl-1 H-benzimidazol acid ethyl ester and the salts thereof | |
| JP6313343B2 (ja) | 有機化合物の製剤 | |
| JPWO2005092336A1 (ja) | 溶出制御製剤とその製造方法 | |
| US20130109722A1 (en) | Use of dabigatran etexilate for treating patients with pulmonary hypertension | |
| US20110306640A1 (en) | Dabigatran in tumour therapy | |
| US20140187563A1 (en) | Combination therapy in treatment of oncological and fibrotic diseases | |
| EP3733167A1 (en) | Novel fine particle coating (drug-containing hollow particle and method for manufacturing same) | |
| TW200920348A (en) | Combination of picotamide with nafronyl | |
| HK1154499A (en) | Dabigatran for percutaneous interventional cardiac catheterisation | |
| HK1078792B (en) | Form of presentation for 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino] propionic acid ethyl ester to be administered orally | |
| HK1135337A (en) | Orally administered pharmaceutical composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20110217 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |